Abbott (ABT) Faces 20% Drop Amid Earnings Concerns and Lawsuit

AI Summary

Abbott Laboratories (ABT) has seen its stock decline 20% this year, influenced by a recent earnings report and ongoing legal issues concerning its special baby formula. Jim Cramer highlighted that Abbott recently acquired Exact Sciences for approximately $21 billion, a deal representing a 51% premium over its prior trading price, marking the largest healthcare merger in two years. Despite this acquisition, Abbott's stock has fallen more than $6 in two days following the announcement. Investors are cautious and awaiting additional insights during the upcoming earnings call to assess future growth potential.